Verrica reports YCANTH demand growth, sets mid-2027 wart data, secures new credit facility
Verrica posted record YCANTH dispensing volume in Q2 2026 and said its new $27.5 million credit facility could stretch cash into 2028.
Verrica Pharmaceuticals said YCANTH dispensed applicator units for the second quarter of 2026 reached 19,626, an increase of about 46% from the second quarter of 2025, and up about 28% from the prior quarter.1
On the pipeline side, the company said on June 22, 2026, the first U.S. patient was dosed in COVE-3, the second pivotal trial in its global Phase 3 program testing YCANTH (VP-102) for common warts in the U.S. and Japan.1 Enrollment continued in the first pivotal study, COVE-2, during the quarter.1 The company reiterated that based on current projections, it expects topline data from the program in mid-2027.1
In its basal cell carcinoma program, Verrica said on May 5, 2026, it presented Phase 2 data on possible abscopal effects of its oncolytic peptide VP-315 (ruxotemitide) at the 2026 Society for Investigative Dermatology Annual Meeting.1
On financing, the company disclosed that on August 6, 2026, it entered into a credit agreement for up to $27.5 million with an entity controlled by Paul B. Manning, Verrica's Chairman and largest shareholder.1 Verrica said based on its current operating plan, it believes the full $27.5 million potentially available under the facility could extend its cash runway into 2028.1
On the balance sheet, cash was $11,198 thousand as of June 30, 2026, compared with $30,147 thousand as of December 31, 2025.1 Total revenue for the quarter was $5.9 million, compared with $12.7 million in the same quarter of 2025.1 Net loss for the quarter was $13.2 million, or $0.62 per share, compared with net income of $0.2 million, or $0.02 per share, a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.